Bb Biotech

Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
  • TickerBIO
  • ISINCH0038389992
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland
Anthony Dick ...
  • Michael Foundoukidis

ODDO BHF Small & MIDCAP MORNING NEWS - 07/24/2020

The shock caused by the COVID-19 pandemic is much bigger than the previous impacts seen since the Bureau Veritas IPO (October 2007), whether from the financial crisis (2008-2009), the sudden drop in oil prices (2014-2015) or the trade war (2019). Q2 2020 results will show historically large organic declines (double digits in some cases) even though sector groups theoretically have resilient and diversified profiles. Eurofins and Bureau Veritas are our Top Picks. We downgrade Applus to...

Anthony Dick ...
  • Michael Foundoukidis

ODDO BHF Small & MIDCAP MORNING NEWS - 24/07/2020

Le choc du COVID-19 dépasse largement les précédents impacts négatifs rencontrés depuis l’introduction en Bourse de Bureau Veritas (octobre 2007), que ce soit la crise financière (2008-2009), la chute brutale du cours du pétrole (2014-2015) ou la guerre commerciale (2019). Ces T2 2020 auront un caractère historique par l’ampleur de leur régression organique (à deux chiffres parfois) malgré des profils théoriquement résilients et diversifiés. Eurofins et Bureau Veritas sont nos valeurs...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : Q2 boosted by the recovery in the markets and positive newsflow

>Q2 boosted by rebound in the markets… - This morning BB Biotech reported its Q2 2020 results. The holding company's share price gained 32.9% in euros and 32.1% in Swiss franc over the quarter, reflecting the recovery that began in Q2 as equity markets recovered. The NAV of the portfolio rose by 48.2% in CHF, by 47.7% in euro sand by 51.2% in US dollars, outperforming the reference index the NBI (Nasdaq Biotechnology Index), which rose 26.9% in USD in the period. This...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : T2 boosté par la recovery sur les marchés et un newsflow positif

>T2 sous l’impulsion du rebond des marchés… - BB Biotech publie ce matin ses chiffres au titre du T2 2020. Le titre de la holding a gagné 32.9% en € et 32.1% en CHF sur le trimestre reflétant la recovery amorcée au T2 à l’instar des marchés equities. La NAV du portefeuille a progressé quant à elle de 48.2% en CHF, de 47.7% en € et de 51.2% en $ surperformant son indice de référence le NBI (Nasdaq Biotechnology Index) qui a lui gagné 26.9% (en $) sur la période. Il en ...

BB Biotech Ag: 1 director sold

A director at BB Biotech Ag sold 500,000 shares at 59.400CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : Q2 boosted by the recovery in the markets and positive newsflow

>Q2 boosted by rebound in the markets… - This morning BB Biotech reported its Q2 2020 results. The holding company's share price gained 32.9% in euros and 32.1% in Swiss franc over the quarter, reflecting the recovery that began in Q2 as equity markets recovered. The NAV of the portfolio rose by 48.2% in CHF, by 47.7% in euro sand by 51.2% in US dollars, outperforming the reference index the NBI (Nasdaq Biotechnology Index), which rose 26.9% in USD in the period. This...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : T2 boosté par la recovery sur les marchés et un newsflow positif

>T2 sous l’impulsion du rebond des marchés… - BB Biotech publie ce matin ses chiffres au titre du T2 2020. Le titre de la holding a gagné 32.9% en € et 32.1% en CHF sur le trimestre reflétant la recovery amorcée au T2 à l’instar des marchés equities. La NAV du portefeuille a progressé quant à elle de 48.2% en CHF, de 47.7% en € et de 51.2% en $ surperformant son indice de référence le NBI (Nasdaq Biotechnology Index) qui a lui gagné 26.9% (en $) sur la période. Il en ...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : Post Q1 2020 update: Neutral rating reiterated – target price of € 64

>Q1 affected by the COVID-19 pandemic - Last Friday, BB Biotech published its Q1 2020 results, with the holding company share having fallen 14.8% in € and 15.7% in CHF in the quarter, reflecting the market sell-off as a result of the COVID-19 pandemic (variations including the payment of dividends). The portfolio performance was a decline of 22% in CHF, 20.1% in € and 21.4% in $ resulting in a net loss of CHF 758m in the period (vs +CHF 890m in Q1 2019). Note that the...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : Update post T1 2020 : Neutre réitéré, OC de 64 €

>Un T1 impacté par la pandémie COVID-19 - BB Biotech a publié vendredi dernier ses résultats du T1 2020, alors que le titre de la holding a reculé de 14.8% en € et de 15.7% en CHF sur le trimestre reflétant le sell-off sur les marchés consécutif à la pandémie COVID-19 (variations incluant le paiement des dividendes). La performance du portefeuille a reculé quant à elle de 22% en CHF, de 20.1% en € et de 21.4% en $ résultant en une perte nette de 758 MCHF sur la périod...

Martial Descoutures ...
  • Oussema Denguir

BB Biotech AG : A Q1 2020 performance impacted by the pandemic

>Q1 performances - BB Biotech published its Q1 2020 results this morning. The holding company's share price fell by 14.8% in euro and 15.7% in Swiss franc over the quarter reflecting the sell-off in the markets following the impact of the COVID-19 pandemic (changes including the dividend payment). Over the same period, the portfolio's performance declined by 22% in Swiss francs, 20.1% in euro and 21.4% in dollars compared to a 10.3% (in dollars) decline in its benchm...

Anthony Dick ...
  • Michael Foundoukidis

ODDO BHF Small & MIDCAP MORNING NEWS - 07/24/2020

The shock caused by the COVID-19 pandemic is much bigger than the previous impacts seen since the Bureau Veritas IPO (October 2007), whether from the financial crisis (2008-2009), the sudden drop in oil prices (2014-2015) or the trade war (2019). Q2 2020 results will show historically large organic declines (double digits in some cases) even though sector groups theoretically have resilient and diversified profiles. Eurofins and Bureau Veritas are our Top Picks. We downgrade Applus to...

Anthony Dick ...
  • Michael Foundoukidis

ODDO BHF Small & MIDCAP MORNING NEWS - 24/07/2020

Le choc du COVID-19 dépasse largement les précédents impacts négatifs rencontrés depuis l’introduction en Bourse de Bureau Veritas (octobre 2007), que ce soit la crise financière (2008-2009), la chute brutale du cours du pétrole (2014-2015) ou la guerre commerciale (2019). Ces T2 2020 auront un caractère historique par l’ampleur de leur régression organique (à deux chiffres parfois) malgré des profils théoriquement résilients et diversifiés. Eurofins et Bureau Veritas sont nos valeurs...

Baptiste Lebacq ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Jean-François Granjon
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Salma Bouraoui
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 04/30/2020

...

Baptiste Lebacq ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Jean-François Granjon
  • Jerôme Bodin
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Salma Bouraoui
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 30/04/2020

...

Alfred Glaser ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Nicolas David
  • Nicolas Thorez
  • Oussema Denguir
  • Roland Pfaender,MBA,CFA,CCRA

ODDO BHF Small & MIDCAP MORNING NEWS - 04/24/2020

...

BB BIOTECH AG sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of BB BIOTECH AG (CH), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 12, 2020, the closing price was CHF 64.25 and its target price was estimated at CHF 52.78.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch